An analysis of longer-term PALOMA safety data finds that palbociclib plus endocrine therapy is not associated with specific cumulative or delayed toxicities.
Journal of the National Cancer Institute
Original Article: Palbociclib and Endocrine Therapy for Advanced Breast Cancer